Acta Scientific Microbiology (ISSN: 2581-3226)

Editorial Volume 6 Issue 3

Bivalent COVID-19 Vaccines

Attapon Cheepsattayakorn1,3*, Ruangrong Cheepsattayakorn2 and Porntep Siriwanarangsun3

110th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

2Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

3Faculty of Medicine, Western University, Pathumtani Province, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: January 25, 2023; Published: February 01, 2023

Particularly, the Omicron and its subvariants [1], such as BA.4, BA.5, BQ.1, BQ.1.1, BF.7, XBB, and XBB.1 [2] have triggered COVID-19 pandemic waves around the world [1]. In January and February 2022, a containing 15 µg of mRNA directed against the SARS-CoV-2 (COVID-19) ancestral strain and 15 µg directed against BA.1 bivalent COVID-19 vaccine was produced by Pfizer-BioNTech, whereas 25 µg of mRNA directed against the same two strains was produced by Moderna [2]. On August 31, 2022, United States Food and Drug Administration (US FDA) authorized the use of Pfizer-BioNTech (Figure 1) [1] and Moderna (Figure 2) [1] bivalent COVID-19 vaccines as a single booster dose in persons 12 years of age and above and in persons 18 years of age and above, respectively [3], whereas Barouch., et al. revealed no impression of CD4+ or CD8+ T-cell different response between bivalent-booster group and monovalent-booster group [2].

References

  1. Biosystem Acro. “Polyvalent, bivalent, and variant COVID-19 vaccines” (2023).
  2. Offit PA. “Bivalent COVID-19 vaccines-a cautionary tale”. The New England Journal of Medicine (2023).
  3. United States Food and Drug Administration (2022).

Citation

Citation: Attapon Cheepsattayakorn., et al. “Bivalent COVID-19 Vaccines". Acta Scientific Microbiology 6.3 (2023): 01-02.

Copyright

Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US